Business Context and Reporting Period
Company: REGENXBIO Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2018
Event: The Company entered into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the offering include:
- Shares Offered: 2,700,000 shares of common stock.
- Offering Price: $65.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 405,000 additional shares.
- Expected Net Proceeds: Approximately $164.3 million (base case) or $189.0 million (if option fully exercised), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Expected Closing Date: August 14, 2018.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of the underwriting agreement with Morgan Stanley & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Barclays Capital Inc. This represents a significant increase in the Company's capital base pending the closing of the transaction.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to an effective shelf registration statement on Form S-3. The press release announcing the pricing was issued on August 10, 2018.
Risks and Contingencies:
- The closing of the offering is subject to the satisfaction of customary closing conditions.
- The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions.
- Certain underwriters and their affiliates have provided and may continue to provide investment banking and other financial services to the Company for customary fees.
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 14, 2018).
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 405,000 shares.
- Review the final net proceeds received after all underwriting discounts and expenses are finalized.
- Examine the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.